Q-omics provides the consensus-scored ZNF431 profile across patient tissues and cancer cell-line models. ZNF431 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF431 is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, ZNF431 RNA expression shows 21,031 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where ZNF431 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF431 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF431 survival associations across molecular data types. ZNF431 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF431 RNA expression–survival associations across cancer types. High ZNF431 expression shows unfavorable associations in UVM, KIRC, KICH and HNSC, but favorable associations in LAML and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF431 RNA expression.
This table summarizes ZNF431 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF431. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF431 shows higher tumor expression in BLCA, LIHC, COAD, CHOL, KICH and KIRP. The BLCA box plot shows higher ZNF431 RNA expression in tumor versus normal tissue (log2 FC = +1.202, t-test p < 0.001).
This table shows molecular features associated with ZNF431 in patient tissues and cancer cell lines. In patient samples, ZNF431 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF431 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
